AgeX Therapeutics Inc.

1.47-0.0300-2.00%Vol 164.51K1Y Perf 82.50%
Apr 16th, 2021 16:00 DELAYED
BID1.45 ASK1.48
Open1.50 Previous Close1.50
Pre-Market- After-Market-
 - -  - -%
Target Price
- 
Analyst Rating
— — 0.00
Potential %
- 
Finscreener Ranking
 —    -
Insiders Trans % 3/6/12 mo.
-/-/- 
Value Ranking
+     37.70
Insiders Value % 3/6/12 mo.
-/-/- 
Growth Ranking
 —    -
Insiders Shares Cnt. % 3/6/12 mo.
-/-/- 
Income Ranking
 —    -
Market Cap55.76M 
Earnings Rating
Neutral
Price Range Ratio 52W %
24.63 
Earnings Date
13th May 2021

Today's Price Range

1.431.52

52W Range

0.66603.93

Summary:

Sell

Technical Indicators: Sell
Moving Averages: Strong Sell
Performance
1 Week
-9.82%
1 Month
-22.22%
3 Months
-20.11%
6 Months
-22.63%
1 Year
82.50%
3 Years
-
5 Years
-
10 Years
-

TickerPriceChg.Chg.%
AGE1.47-0.0300-2.00
AAPL134.16-0.3400-0.25
GOOG2 297.761.10000.05
MSFT260.741.24000.48
XOM56.66-0.3200-0.56
WFC43.841.60003.79
JNJ162.241.85001.15
FB306.18-1.6400-0.53
GE13.39-0.1600-1.18
JPM153.301.13000.74
Earnings HistoryEstimateReportedSurprise %
Q03 2020--0.07-
Q02 2020--0.07-
Q01 2020--0.08-
Q04 2019--0.08-
Q03 2019--0.09-
Q02 2019--0.08-
Q01 2019--0.09-
----
Earnings Per EndEstimateRevision %Trend
----
----
----
----
Next Report Date13th May 2021
Estimated EPS Next Report-
Estimates Count-
EPS Growth Next 5 Years %-
Volume Overview
Volume164.51K
Shares Outstanding37.94M
Trades Count544
Dollar Volume292.53K
Avg. Volume335.84K
Avg. Weekly Volume123.77K
Avg. Monthly Volume179.44K
Avg. Quarterly Volume352.90K

AgeX Therapeutics Inc. (AMEX: AGE) stock closed at 1.47 per share at the end of the most recent trading day (a -2% change compared to the prior day closing price) with a volume of 164.53K shares and market capitalization of 55.76M. Is a component of indices and it is traded on AMEX exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 17 people. AgeX Therapeutics Inc. CEO is Michael D. West.

The one-year performance of AgeX Therapeutics Inc. stock is 82.5%, while year-to-date (YTD) performance is -3.29%. AGE stock has a five-year performance of %. Its 52-week range is between 0.666 and 3.93, which gives AGE stock a 52-week price range ratio of 24.63%

AgeX Therapeutics Inc. currently has a PE ratio of -5.70, a price-to-book (PB) ratio of 14.33, a price-to-sale (PS) ratio of 45.42, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -180.67%, a ROC of -319.78% and a ROE of 804.46%. The company’s profit margin is -%, its EBITDA margin is -499.00%, and its revenue ttm is $1.35 Million , which makes it $0.04 revenue per share.

Of the last four earnings reports from AgeX Therapeutics Inc., there were 0 positive earnings surprise and 0 negative earnings surprise. The company has EPS estimate of $0.00 for the next earnings report. AgeX Therapeutics Inc.’s next earnings report date is 13th May 2021.

The consensus rating of Wall Street analysts for AgeX Therapeutics Inc. is (), with a target price of $, which is 0.00% compared to the current price. The earnings rating for AgeX Therapeutics Inc. stock is (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

AgeX Therapeutics Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

AgeX Therapeutics Inc. has a Sell technical analysis rating based on Technical Indicators (ADX : 27.35, ATR14 : 0.17, CCI20 : -150.10, Chaikin Money Flow : -0.15, MACD : -0.15, Money Flow Index : 32.01, ROC : -9.82, RSI : 41.61, STOCH (14,3) : 10.16, STOCH RSI : 0.00, UO : 38.62, Williams %R : -89.84), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of AgeX Therapeutics Inc. in the last 12-months were: Michael D. West (Option Excercise at a value of $0)

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
0
0
0
Moderate Buy
0
0
0
Hold
0
0
0
Moderate Sell
0
0
0
Strong Sell
0
0
0
Summary Rating---

AgeX Therapeutics Inc.

AgeX Therapeutics Inc is a biotechnology company engaged in the development and commercialization of novel therapeutics targeting human aging. The firm through its PureStem and induced Tissue Regeneration (iTR) technologies develop innovative medicines designed to address some of the unsolved problems in aging. Its PureStem derived cell-based therapeutic candidates in development are AGEX-VASC1 and AGEX-BAT1. And iTR drug-based therapeutic candidates in development are AGEX-iTR1547 and Renelon.

CEO: Michael D. West

Telephone: +1 510 871-4190

Address: 1010 Atlantic Avenue, Alameda 94501, CA, US

Number of employees: 17

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

100%0%

Bearish Bullish

52%48%

Bearish Bullish

55%45%

Bearish Bullish

65%35%

News

Stocktwits